Table 1.
BoNT-A preparations currently approved in the US or Europe for treatment of moderate to severe glabellar lines in adults [7,8,9,10,11,12,13,14].
| Generic (Trade Name[s]) | Manufacturer/First Approved for Glabellar Lines | Dose (U)/no. Injection Points | Standard Total Dose for Glabellar Lines (U) | Volume (mL) Per Injection Point | Duration of Effect (as Stated in the License) |
|---|---|---|---|---|---|
| OnabotulinumtoxinA (Botox Cosmetic®/Vistabel®) |
Allergan /2002 |
4/5 | 20 | 0.1 | Approx. 3–4 months |
| AbobotulinumtoxinA (Dysport®/Azzalure®) |
Ipsen/2009 | 10/5 | 50 | 0.05, 0.08 (US), 0.05, 0.1 (Europe) | Up to 5 months |
| IncobotulinumtoxinA (Xeomin®/Bocouture®) |
Merz/2010 a | 4/5 | 20 | 0.04 to 0.1 | Up to 4 months |
| PrabotulinumtoxinA (Jeuveau®) |
Evolus/2019 | 4/5 | 20 | 0.1 | Not stated |
a According to UK SmPC. Approx., approximately; U, standard potency unit (not interchangeable between products); US, United State.